Skip to content
Inciteful Med

Understanding Systemic Lupus Erythematosus (SLE)

Last updated:

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease where an overactive immune system mistakenly attacks healthy tissues. While it can affect multiple organs, modern treatments allow most patients to manage their symptoms effectively and live a normal lifespan.

Key Takeaways

  • • Systemic Lupus Erythematosus (SLE) is an autoimmune disease, not a form of cancer or a contagious infection.
  • • Lupus occurs when hyperactive B-cells and autoantibodies mistakenly attack healthy tissues like the skin, joints, and kidneys.
  • • Childhood-onset SLE (cSLE) is typically more aggressive than adult-onset lupus and requires intensive treatment and monitoring.
  • • With modern targeted therapies, the vast majority of people with lupus can expect to live a normal or near-normal lifespan.
  • • The primary goal of lupus treatment is to reach a Low Disease Activity State (LLDAS) or clinical remission.

Receiving a diagnosis of Systemic Lupus Erythematosus (SLE)—often simply called lupus—can feel like the world has suddenly shifted beneath your feet. It is natural to feel overwhelmed, anxious, or even angry. Please know that your feelings are valid, and while lupus is a serious chronic condition, it is a manageable one. You are not alone in this journey, and modern medicine has made incredible strides in helping people with lupus live full, active lives [1][2].

What is SLE?

Systemic Lupus Erythematosus (SLE) is an autoimmune disease, which means your immune system, which normally protects you from germs, becomes confused and begins to attack your own healthy tissues [3][4]. The word “systemic” means it can affect many different parts of your body, including your skin, joints, kidneys, and heart [5].

It is important to clarify what lupus is not:

  • It is not a form of cancer.
  • It is not contagious; you cannot “catch” it from someone or give it to others.
  • It is not an immunodeficiency (like HIV/AIDS); rather than being “weak,” your immune system is overactive and misdirected [3]. However, it is important to know that the resulting immune dysregulation, along with the medications used to treat lupus, will suppress your immune system and make it harder for your body to fight off everyday infections [6][7].

How Lupus Works in Your Body

The biological “engine” of lupus involves a few key players in your immune system:

  • B-cells: These are a type of white blood cell. In lupus, B-cells become hyperactive and live longer than they should [3][8].
  • Autoantibodies: Normally, antibodies attack viruses. In SLE, B-cells produce autoantibodies (like ANA, anti-dsDNA, and anti-Smith) that mistakenly target your own DNA and proteins [9][10].
  • Interferons: These are signaling proteins that usually “interfere” with viruses. In many lupus patients, the body produces too much Type I Interferon, which acts like a constant “false alarm,” keeping the immune system in a state of high inflammation [11][12].

Who Does Lupus Affect?

Lupus can affect anyone, but it shows up more frequently in certain groups. It is much more common in women than in men, often developing during childbearing years [13].

In the United States, there are significant racial and ethnic disparities in how lupus manifests:

  • Black/African American individuals have the highest rates of SLE, with incidence rates up to 5 to 9 times higher than White individuals [13][14].
  • Hispanic and Asian individuals also face a higher risk and may experience more severe disease symptoms compared to White patients [15][16].
  • Researchers are working to understand these differences, which likely stem from a complex mix of genetics, environmental factors, and social influences [17][18].

Childhood-Onset (cSLE) vs. Adult-Onset

When lupus is diagnosed in a child or teenager (before age 18), it is called Childhood-onset SLE (cSLE). It differs from the adult version in several key ways:

  • More Aggressive: cSLE is generally more severe at the time of diagnosis and progresses more quickly than adult-onset lupus [19][20].
  • Higher Organ Involvement: Children are more likely to develop Lupus Nephritis and central nervous system involvement early in their journey [21][22].
  • Treatment Intensity: Because the disease is often more active, children typically require more intensive immunosuppressive therapy [19][23].
  • Long-term Monitoring: Because children have many decades of life ahead of them, doctors focus heavily on minimizing “steroid-related damage,” such as impacts on growth, bone density, and eye health [24][20].

Three Stabilizing Facts for Your Journey

When the “panic spiral” starts, keep these three evidence-based facts in mind:

  1. Life Expectancy is Improving: Due to better diagnostic tools and treatments, the vast majority of people diagnosed with lupus today can expect to live a normal or near-normal lifespan [1].
  2. New Treatments are Available: We are in a “golden age” of lupus research. Within the last decade, several new targeted therapies (like belimumab) have been approved specifically to treat SLE, offering more options than ever before [2][25].
  3. Remission is the Goal: Your care team’s goal is to reach a Lupus Low Disease Activity State (LLDAS) or remission. With the right combination of medication and lifestyle adjustments, many patients go through long periods where they have few to no symptoms [26].

Frequently Asked Questions

What is systemic lupus erythematosus (SLE)?
SLE, commonly known as lupus, is a chronic autoimmune disease where your immune system mistakenly attacks healthy tissues. This can cause inflammation in various parts of the body, including the skin, joints, kidneys, and heart.
Is lupus a type of cancer or is it contagious?
No, lupus is not a form of cancer and it is not contagious. It is an autoimmune condition driven by an overactive immune system, rather than an immunodeficiency or an infection you can catch from someone else.
What is the difference between adult-onset lupus and childhood-onset SLE (cSLE)?
Childhood-onset SLE is diagnosed before age 18 and is generally more aggressive than adult-onset lupus. Children with cSLE often have a higher risk of organ involvement, such as kidney issues, and typically require more intensive treatments.
Can people with lupus live a normal lifespan?
Yes, thanks to advances in diagnostic tools and targeted therapies, the vast majority of people diagnosed with lupus today can expect to live a normal or near-normal lifespan. The primary goal of treatment is to achieve remission or a low disease activity state.
What do autoantibodies like ANA and anti-dsDNA mean for my lupus diagnosis?
Autoantibodies are proteins produced by your immune system that mistakenly target your own DNA and tissues. Measuring specific autoantibodies like ANA, anti-dsDNA, and anti-Smith helps your doctor confirm a lupus diagnosis and monitor your specific disease profile.

Questions for Your Doctor

  • • Based on my lab results, what is my specific ANA (Antinuclear Antibody) titer and pattern, and what does that tell you about my case?
  • • Which specific autoantibodies, like anti-dsDNA or anti-Smith, were found in my bloodwork?
  • • What is our primary goal for my 'Lupus Low Disease Activity State' (LLDAS), and how will we measure our progress toward it?
  • • Are there any signs of organ involvement, such as in my kidneys or nervous system, that we should be monitoring closely right now?
  • • What is the long-term plan for my medication, and how will we balance controlling the disease with minimizing side effects?

Questions for You

  • • What were the first symptoms that led me to seek medical advice, and have they changed or moved to different parts of my body since then?
  • • When I feel a 'flare' coming on, what does it feel like (e.g., extreme fatigue, joint pain, or a specific rash)?
  • • How has this diagnosis affected my daily energy levels and my ability to do the things I enjoy?
  • • What are my biggest fears or concerns about living with lupus, and who can I talk to for emotional support?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Psychological Implications to the Therapy of Systemic Lupus Erythematosus.

    Warchoł-Biedermann K, Mojs E, Sikorska D, et al.

    International journal of environmental research and public health 2022; (19(23)) doi:10.3390/ijerph192316021.

    PMID: 36498095
  2. 2

    Belimumab for the treatment of pediatric patients with lupus nephritis.

    Stohl W, Kwok A

    Expert opinion on biological therapy 2023; (23(3)):243-251 doi:10.1080/14712598.2023.2178297.

    PMID: 36750049
  3. 3

    B cells biology in systemic lupus erythematosus-from bench to bedside.

    Zhao L, Ye Y, Zhang X

    Science China. Life sciences 2015; (58(11)):1111-25 doi:10.1007/s11427-015-4953-x.

    PMID: 26563177
  4. 4

    T-bet-expressing B cells contribute to the autoreactive plasma cell pool in Lyn-/- mice.

    Ottens K, Schneider J, Satterthwaite AB

    European journal of immunology 2023; (53(8)):e2250300 doi:10.1002/eji.202250300.

    PMID: 37134326
  5. 5

    Orofacial manifestations of rheumatoid arthritis and systemic lupus erythematosus: a narrative review.

    Thomas DC, Kohli D, Chen N, et al.

    Quintessence international (Berlin, Germany : 1985) 2021; (52(5)):454-466 doi:10.3290/j.qi.b1043985.

    PMID: 33688716
  6. 6

    Mitochondrial dysfunction is a potential key mechanism for atherosclerosis predisposition in patients with systemic lupus erythematosus.

    Liu X, Wang C, Guan X

    Journal of autoimmunity 2025; (157()):103488 doi:10.1016/j.jaut.2025.103488.

    PMID: 40966991
  7. 7

    [Analysis of 20-year survival rate and prognostic indicators of systemic lupus erythematosus].

    Wang ZR, Ren LM, Li R, et al.

    Zhonghua yi xue za zhi 2019; (99(3)):178-182 doi:10.3760/cma.j.issn.0376-2491.2019.03.005.

    PMID: 30669759
  8. 8

    Organ-based characterization of B cells in patients with systemic lupus erythematosus.

    Wang Y, Zhao R, Liang Q, et al.

    Frontiers in immunology 2025; (16()):1509033 doi:10.3389/fimmu.2025.1509033.

    PMID: 39917309
  9. 9

    Relationship between clinical manifestations and serological profile in patients affected by Systemic Lupus Erythematosus.

    Nicola S, Borrelli R, Corradi F, et al.

    Frontiers in immunology 2024; (15()):1390642 doi:10.3389/fimmu.2024.1390642.

    PMID: 39221240
  10. 10

    Clinical and serological associations of autoantibodies in patients with systemic lupus erythematosus.

    Correa-Rodríguez M, Pocovi-Gerardino G, Callejas-Rubio JL, et al.

    Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2021; (69(8)):1417-1425 doi:10.1136/jim-2021-001887.

    PMID: 34183445
  11. 11

    Antibodies against type I IFN: The bad guys self-restrain in systemic lupus erythematosus.

    Fillatreau S

    Cell reports. Medicine 2023; (4(1)):100903 doi:10.1016/j.xcrm.2022.100903.

    PMID: 36652912
  12. 12

    Human effector B lymphocytes express ARID3a and secrete interferon alpha.

    Ward JM, Ratliff ML, Dozmorov MG, et al.

    Journal of autoimmunity 2016; (75()):130-140 doi:10.1016/j.jaut.2016.08.003.

    PMID: 27522115
  13. 13

    The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project.

    Dall'Era M, Cisternas MG, Snipes K, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(10)):1996-2005 doi:10.1002/art.40191.

    PMID: 28891237
  14. 14

    Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study.

    Tian J, Zhang D, Yao X, et al.

    Annals of the rheumatic diseases 2023; (82(3)):351-356 doi:10.1136/ard-2022-223035.

    PMID: 36241363
  15. 15

    Towards an understanding of the biopsychosocial determinants of CVD in SLE: a scoping review.

    Shantz E, Elliott SJ, Sperling C, et al.

    Lupus science & medicine 2024; (11(2)) doi:10.1136/lupus-2024-001155.

    PMID: 39053931
  16. 16

    Racial differences in persistent glucocorticoid use patterns among medicaid beneficiaries with incident systemic lupus erythematosus.

    Chandler MT, Santacroce LM, Costenbader KH, et al.

    Seminars in arthritis and rheumatism 2023; (58()):152122 doi:10.1016/j.semarthrit.2022.152122.

    PMID: 36372014
  17. 17

    Addressing the research gap: access to care hinders genetic discovery in systemic lupus erythematosus patients throughout the African diaspora.

    Hwang J, Dzifa Dey I, Ayanlowo O, et al.

    Frontiers in genetics 2024; (15()):1414490 doi:10.3389/fgene.2024.1414490.

    PMID: 39211738
  18. 18

    The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous.

    Woo JMP, Parks CG, Jacobsen S, et al.

    Journal of internal medicine 2022; (291(6)):755-778 doi:10.1111/joim.13448.

    PMID: 35143075
  19. 19

    Revisiting Childhood-Onset Systemic Lupus Erythematosus.

    Avar-Aydın PÖ, Brunner HI

    Turkish archives of pediatrics 2024; (59(4)):336-344 doi:10.5152/TurkArchPediatr.2024.24097.

    PMID: 39102578
  20. 20

    Disease characteristics in patients with juvenile- and adult-onset systemic lupus erythematosus: A multi-center comparative study.

    Gamal SM, Fouad N, Yosry N, et al.

    Archives of rheumatology 2022; (37(2)):280-287 doi:10.46497/ArchRheumatol.2022.8888.

    PMID: 36017206
  21. 21

    The unique challenges of childhood-onset systemic lupus erythematosus and lupus nephritis patients: a proposed framework for an individualized transitional care plan.

    Renson T, Lightstone L, Ciurtin C, et al.

    Pediatric nephrology (Berlin, Germany) 2025; (40(10)):3045-3053 doi:10.1007/s00467-024-06654-5.

    PMID: 40080183
  22. 22

    Distinct clinical correlates of immune thrombocytopenic purpura at diagnosis of childhood-onset and adult SLE.

    Esteves GCX, Gormezano NWS, Pereira OL, et al.

    Modern rheumatology 2018; (28(4)):649-653 doi:10.1080/14397595.2017.1386836.

    PMID: 29067848
  23. 23

    Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options.

    Smith EMD, Lythgoe H, Midgley A, et al.

    Clinical immunology (Orlando, Fla.) 2019; (209()):108274 doi:10.1016/j.clim.2019.108274.

    PMID: 31678365
  24. 24

    Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus.

    Heshin-Bekenstein M, Trupin L, Yelin E, et al.

    Seminars in arthritis and rheumatism 2019; (49(2)):267-272 doi:10.1016/j.semarthrit.2019.05.010.

    PMID: 31235075
  25. 25

    An Uncommon Correlation of Rheumatoid Arthritis and Lupus Nephritis: A Case Report on the Unusual Progression of Lupus Nephritis.

    Lam LC, Yadav VD, Mihal VJ

    Cureus 2022; (14(8)):e27620 doi:10.7759/cureus.27620.

    PMID: 36134049
  26. 26

    Multidisciplinary care in patients with systemic lupus erythematosus: a randomized controlled trial in China.

    Zhang L, Geng S, Qian L, et al.

    International journal of clinical pharmacy 2019; (41(5)):1247-1255 doi:10.1007/s11096-019-00870-y.

    PMID: 31240553

This page provides an overview of Systemic Lupus Erythematosus (SLE) for educational purposes. Always consult your rheumatologist or healthcare team for personalized medical advice and treatment planning.

Stay up to date

Get notified when new research about Systemic lupus erythematosus is published.

No spam. Unsubscribe anytime.